BioSpace News Archive

Be Biopharma, Inc., a company pioneering the discovery and development of Engineered B Cell Medicines, announced that Chief Executive Officer Joanne Smith-Farrell,Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, CA on Wednesday, January 10, 2024.

Hi-Tech Pharmaceuticals, a leading manufacturer of cutting-edge dietary supplements and weight management supplements, is proud to announce the launch of its latest product, SLIMAGLUTIDE®.

Trevena, Inc. announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share and associated warrant in a private placement, for gross proceeds to the Company of approximately $1.946 million.

NKGen Biotech, Inc. announced the dosing of the first patient in its Phase 1/2a trial evaluating SNK01, a cryopreserved autologous, non-genetically modified NK cell therapy product with enhanced cytotoxicity and activating receptor expression.

Inspira Technologies OXY BHN Ltd. announces the closing of its previously announced registered direct offering of 3,031,250 ordinary shares, at a purchase price of $1.28 per ordinary share.

Dr. Larry Gold, the founder of SomaLogic, Inc. and Dr. Jason Cleveland, SomaLogic’s current Chief Technology Officer, are issuing the below letter to SomaLogic’s stockholders regarding their opposition to the Company’s proposed merger with Standard BioTools, Inc. .

Enpro Inc. announced that it has entered into a definitive agreement to acquire Advanced Micro Instruments, Inc., a leading provider of highly-engineered, application-specific analyzers and sensing technologies that monitor critical parameters to maintain infrastructure integrity, enable process efficiency, enhance safety, and facilitate the clean energy transition.

CytoSorbents Corporation announces an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board analysis for the pivotal U.S. and Canadian STAR-T randomized controlled trial.

Palisade Bio, Inc. announced the receipt of the second milestone payment to Giiant from the US Crohn’s and Colitis Foundation, through its Inflammatory Bowel Disease Ventures program.

Bionano Genomics, Inc., announced significant upgrades to its pipeline for analysis of optical genome mapping data in its VIA™ software for applications in constitutional genetic disease.